Patents Examined by Kevin E. Weddington
  • Patent number: 10668074
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 2, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Patent number: 10662201
    Abstract: A compound of chemical formula I: or chemical formula II: or a pharmaceutical acceptable salt thereof is disclosed. R1, R2, R3, and R4 are independently H, halogen, nitro, hydroxyl, cyano, benzyloxy, C1-C8 straight or branched alkyl, C1-C8 straight or branched haloalkyl, C1-C8 straight or branched alkoxy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 26, 2020
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Xingke Ju, Lei Tian, Nan Qin, Juan Xia, Shaomeng Pei, Han Li, Yuzhi Liu
  • Patent number: 10660876
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 26, 2020
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • Patent number: 10653665
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Patent number: 10653629
    Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 19, 2020
    Assignee: Amorsa Therapeutics, Inc.
    Inventors: Alex Nivorozhkin, Nelson Landrau
  • Patent number: 10653778
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 19, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Wilson Caparros-Wanderely, Suzanne J. Dilly, Olga Pleguezeulos Mateo, Gregory A. Stoloff
  • Patent number: 10646429
    Abstract: The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 12, 2020
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Longsheng Hu, Virginia Streusand Goldman, Josephine A. Minerva, Susan Wendling
  • Patent number: 10639270
    Abstract: A foaming oil cleanser composition and a method of preparing a foaming oil cleanser composition are provided. The foaming oil cleanser composition includes (a) a dialkyl sulfosuccinate, (b) Ricinus Communis Seed Oil, and (c) one or more oils. The foaming oil cleanser composition is essentially free of water and sulfate.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 5, 2020
    Assignee: L'OREAL
    Inventors: William Ronald Feuer, Miao Wang, Wivina Lijo
  • Patent number: 10626122
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Patent number: 10624870
    Abstract: The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: April 21, 2020
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Patent number: 10618911
    Abstract: A compound of chemical formula I: or formula II: or a pharmaceutical acceptable salt thereof is disclosed. R1 is OH or OAc; X is C or N; and R2 is H, alkyl, alkoxy, benzyloxy, haloalkyl, OH, CN, NO2, or halogen, provided that when X is N, R2 is nil.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: April 14, 2020
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Han Li, Yuzhi Liu, Nan Qin, Juan Xia, Shaomeng Pei, Chengyuan Liang, Lei Tian
  • Patent number: 10619027
    Abstract: Provided an agent for suppressing an odor of a polysulfide compound. This agent for suppressing an odor of a polysulfide compound comprises, as an active ingredient, at least one selected from the group consisting, butyl 2-methylbutanoate, ?-terpinene, dipentene, cis-4-heptenal, 1,4-cineol, trimethylhexyl aldehyde, and (+)-limonene oxide, wherein the polysulfide compound is represented by the following formula (I): R1—[S]n—R2 (I) (in the formula, R1 and R2 are the same or different, and each denote a linear-chain or branched-chain alkyl or alkenyl group having 1 to 6 carbon atoms, and n denotes an integer of 2 to 5).
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 14, 2020
    Assignee: KAO CORPORATION
    Inventors: Keiichi Yoshikawa, Naoko Saito
  • Patent number: 10617733
    Abstract: The present invention relates to a pharmaceutical composition comprising non-decarboxylated ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 14, 2020
    Assignee: Rise Life Sciences Corp.
    Inventor: Brooks John Kelly
  • Patent number: 10603292
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kenji Egusa, Takuma Katayama, Kazutoshi Yokoyama, Remko Alexander Bakker, Ngai Hang Victor Chong, Joerg Rippmann
  • Patent number: 10588836
    Abstract: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with without a tacky residue upon drying.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: March 17, 2020
    Assignee: Ecolab USA Inc.
    Inventors: Joseph R. Wegner, Cheryl A. Littau
  • Patent number: 10583133
    Abstract: The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: March 10, 2020
    Assignee: SHILPA MEDICARE LIMITED
    Inventors: Nijaguni Revansiddayya Rudraswamy Math, Sreenivas Reddy, Ravi Vamsi Peri, Krishnamurthy Toppaladoddi, Shivakumar Pradeep
  • Patent number: 10576165
    Abstract: The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: March 3, 2020
    Assignee: Siga Technologies Inc.
    Inventors: Shanthakumar R. Tyavanagimatt, Melialani A. C. L. S. Anderson, William Weimers, Gopi Krishna Kasi, N K Peter Samuel, Tove C. Bolken, Dennis E. Hruby
  • Patent number: 10576063
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 3, 2020
    Assignee: Mercator MedSystems, Inc.
    Inventor: Kirk Patrick Seward
  • Patent number: 10562925
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: February 18, 2020
    Assignee: TOLERO PHARMACEUTICALS, INC.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 10563270
    Abstract: Disclosed are solid forms of menaquinol and processes for obtaining them by chemical or enzymatic reduction of menaquinone. Said solid forms possess high stability to oxidation which allows effective use of menaquinol in the most common formulations wherein vitamin K2 is used.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 18, 2020
    Assignee: Gnosis S.p.A.
    Inventors: Davide Bianchi, Simona Daly, Niccolo Miraglia, Antonella Trentin, Federica Colzani, Francesca Bollini, Cesare Ponzone